Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
Immunomodulatory drug maintenance therapy probably leads to lower progression‐free survival compared with placebo/observation (moderate certainty).
Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).
It is very uncertain whether immunomodulatory drug maintenance therapy changes treatment discontinuation compared with placebo/observation (very low certainty).
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 ‐ total compared with placebo or standard care alone (high certainty).
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes all‐cause mortality at up to day 28 compared with placebo or standard care alone (very low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical worsening: need for invasive mechanical ventilation, or… compared with placebo or standard care alone (high certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard care alone (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Convalescent plasma showed no clear difference in time to symptom resolution (absolute effect calculated for day 12) compared with placebo or standard care alone (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events compared with placebo or standard care alone (low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical improvement: participants discharged from hospital compared with placebo or standard care alone (high certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).